Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Non-Current Debt (2020 - 2022)

Historic Non-Current Debt for Mereo BioPharma (MREO) over the last 3 years, with Q2 2022 value amounting to $20.1 million.

  • Mereo BioPharma's Non-Current Debt fell 1985.55% to $20.1 million in Q2 2022 from the same period last year, while for Jun 2022 it was $20.1 million, marking a year-over-year decrease of 1985.55%. This contributed to the annual value of $19.4 million for FY2021, which is 645.92% down from last year.
  • Mereo BioPharma's Non-Current Debt amounted to $20.1 million in Q2 2022, which was down 1985.55% from $19.4 million recorded in Q4 2021.
  • Over the past 5 years, Mereo BioPharma's Non-Current Debt peaked at $25.1 million during Q2 2021, and registered a low of $18.0 million during Q2 2020.
  • Moreover, its 3-year median value for Non-Current Debt was $20.1 million (2022), whereas its average is $20.8 million.
  • Per our database at Business Quant, Mereo BioPharma's Non-Current Debt surged by 3915.95% in 2021 and then tumbled by 1985.55% in 2022.
  • Quarter analysis of 3 years shows Mereo BioPharma's Non-Current Debt stood at $21.3 million in 2020, then fell by 9.03% to $19.4 million in 2021, then grew by 3.6% to $20.1 million in 2022.
  • Its last three reported values are $20.1 million in Q2 2022, $19.4 million for Q4 2021, and $25.1 million during Q2 2021.